Lyu H, Chen JS, Tang JF, Zhou CF. miR-136: A biomarker in the inflammation-cancer transformation of gastric cancer. World J Gastrointest Oncol 2025; 17(12): 114173 [DOI: 10.4251/wjgo.v17.i12.114173]
Corresponding Author of This Article
Ce-Fan Zhou, PhD, Professor, School of Life and Health Sciences, Institute of Biomedical Research, National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, No. 28 Nanli Road, Wuhan 430068, Hubei Province, China. cefan@hbut.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Dec 15, 2025; 17(12): 114173 Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.114173
miR-136: A biomarker in the inflammation-cancer transformation of gastric cancer
Hao Lyu, Jia-Si Chen, Jing-Feng Tang, Ce-Fan Zhou
Hao Lyu, Jia-Si Chen, Jing-Feng Tang, Ce-Fan Zhou, School of Life and Health Sciences, Institute of Biomedical Research, National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, Wuhan 430068, Hubei Province, China
Co-first authors: Hao Lyu and Jia-Si Chen.
Author contributions: Lyu H and Chen JS contributed equally to this study as co-first authors; Lyu H prepared and wrote the original draft; Chen JS collaboratively drafted the manuscript; Zhou CF contributed to the conceptualization, writing, review, and editing of the manuscript; Tang JF provided some valuable opinions; all authors have reviewed and approved the final version of the manuscript.
Supported by National Natural Science Foundation of China, No. 32270768, No. 82273970, and No. 82370715.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ce-Fan Zhou, PhD, Professor, School of Life and Health Sciences, Institute of Biomedical Research, National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, No. 28 Nanli Road, Wuhan 430068, Hubei Province, China. cefan@hbut.edu.cn
Received: September 15, 2025 Revised: October 11, 2025 Accepted: October 29, 2025 Published online: December 15, 2025 Processing time: 89 Days and 20.4 Hours
Abstract
The study by Chen et al found that miR-136 plays an indispensable role in the inflammation-cancer transformation in gastric cancer (GC). The authors conducted in vivo and in vitro experiments and verified them in conjunction with functional and molecular mechanisms. Their key findings indicate that Helicobacter pylori (H. pylori) activated NF-κB/miR-136/PDCD11 axis to induce the growth of H. pylori-positive GC tumors. And miR-136 is markedly associated with characteristics related to the gastric mucosal histopathological, supporting its use as a diagnostic biomarker and a therapeutic target for early H. pylori-induced GC. Chronic inflammation is one of the important precancerous lesions. With the development of emerging technologies such as multi-omics technology, the pathways linking chronic inflammation to cancer have been extensively elucidated. In this letter, we focus on introducing the molecular mechanisms of chronic inflammation in the development of GC, which will provide new insights for early diagnosis, personalized treatment, and prognosis assessment of GC.
Core Tip: Helicobacter pylori (H. pylori)-induced inflammation plays a crucial role in the development of gastric cancer (GC). A comprehensive understanding of the molecular mechanisms driven by H. pylori infection in the development of GC is essential for the timely diagnosis of tumors and the formulation of corresponding personalized treatment strategies. Reviewing the mechanisms of inflammation-cancer transformation induced by H. pylori infection in GC, will help in identifying potential patient stratification factors and formulating personalized treatment strategies for GC patients.
